Publications & Presentations

Jun 20, 2019

Losmapimod Reduces DUX4 Expression Across Genotypes in FSHD Patient-Derived Myotubes

Alejandro Rojas, Erin Valentine, Joseph Maglio, Anthony Accorsi, Alan Robertson, Ning Shen, Angela Cacace, Lucienne Ronco, Owen Wallace. Fulcrum Therapeutics.

Jun 20, 2019

Phase 1 Clinical Trial of Losmapimod in FSHD

Michelle L. Mellion [1], Lucienne Ronco [1], Drew Thompson [1], Michelle Hage [1], William Tracewell [1], Sander Brooks [2], Emilie van Brummelen [2], Lisa Pagan [2], Umesh Badrising [3], Baziel Van Engelen [4], Geert Jan Groeneveld [2,3], Diego Cadavid [1]
[1] Fulcrum Therapeutics, Cambridge, MA, USA, [2] Centre for Human Drug Research (CHDR), Leiden, NL, [3] Leiden University Medical Centre, Leiden, NL, [4] Radboud University Medical Centre, Nijmegen, NL

Jun 20, 2019

Safety and tolerability of losmapimod, a selective p38α/β MAPK inhibitor, for treatment of FSHD at its root cause

Diego Cadavid, Michelle Mellion, Owen Wallace, Lucienne Ronco, Drew Thompson, Alejandro Rojas, Michelle Hage, Robert Gould. Fulcrum Therapeutics.